[Intensity modulated radiation therapy for 90 untreated nasopharyngeal carcinoma]. 2012

Rui Wei, and Wenjuan Jiang, and Jiqing Su, and Lili He, and Zhen Yang, and Wuzhong Jiang
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.

OBJECTIVE To observe the clinical results and the toxicities of normal tissues in untreated nasopharyngeal carcinoma (NPC) treated with intensity modulated radiation therapy (IMRT). METHODS A total of 90 patients with untreated NPC received IMRT. According to the 1992 Fuzhou staging system, 3 patients were in stage I, 29 in stage II, 26 in stage III, and 32 in stage IVa. For IMRT,the prescription dose was 71.94-77.88 Gy/33f for the planning target volume of the gross tumor volume in the nasopharynx (PGTVnx); 69.96 Gy/33f for the positive neck lymph nodes (GTVnd); 60-66 Gy/33f for the planning target volume of the high risk regions (PTV1); and 50.4-56 Gy/28f for the planning target volume of the low risk regions (PTV2). Chemotherapy included concurrent and adjuvant protocols. The overall survival rate, local control rate, and distant metastasis-free survival rate were estimated by Kaplan-Meier method. Cox regression was used for multivariate analysis. Acute and 1ate toxicities were graded according to RTOG radiation morbidity scoring criteria. RESULTS The median follow-up time was 33 months (12-56 months). The 1-, 2-, 3- and 4-year survival rate was 97.8%, 90.6%, 86% and 80%; the local control tate was 98.8%, 97.5%, 92.1% and 77.4%; and the distant metastasis-free survival rate was 95.3%, 90.7%, 88.4% and 85.8%, respectively. The most serious acute toxicity was irradiated inflammation of mocosa with Grade 1 to 4 of 16.7%, 60%, 23.3% and 0, respectively. In the multivariate analysis, clinical stages were the prognostic factors for the survival rate. The most serious toxicity was salivary gland. The rate of grade xerostomia 1-year after the radiotherapy with Grade 1 to 4 was 18.1%, 9.6%, 0 and 0, respectively. CONCLUSIONS IMRT combined chemotherapy can improve the survival rate, and late adverse reaction is obviously decreased. Local recurrence and distant metastasis are the main reasons for low survival rate.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009303 Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX. Cancer of Nasopharynx,Nasopharyngeal Cancer,Cancer of the Nasopharynx,Nasopharynx Cancer,Nasopharynx Neoplasms,Neoplasms, Nasopharyngeal,Cancer, Nasopharyngeal,Cancer, Nasopharynx,Cancers, Nasopharyngeal,Cancers, Nasopharynx,Nasopharyngeal Cancers,Nasopharyngeal Neoplasm,Nasopharynx Cancers,Nasopharynx Neoplasm,Neoplasm, Nasopharyngeal,Neoplasm, Nasopharynx,Neoplasms, Nasopharynx
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

Rui Wei, and Wenjuan Jiang, and Jiqing Su, and Lili He, and Zhen Yang, and Wuzhong Jiang
June 2015, European annals of otorhinolaryngology, head and neck diseases,
Rui Wei, and Wenjuan Jiang, and Jiqing Su, and Lili He, and Zhen Yang, and Wuzhong Jiang
July 2003, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Rui Wei, and Wenjuan Jiang, and Jiqing Su, and Lili He, and Zhen Yang, and Wuzhong Jiang
October 2010, Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
Rui Wei, and Wenjuan Jiang, and Jiqing Su, and Lili He, and Zhen Yang, and Wuzhong Jiang
January 2022, Journal of medical physics,
Rui Wei, and Wenjuan Jiang, and Jiqing Su, and Lili He, and Zhen Yang, and Wuzhong Jiang
April 2001, International journal of cancer,
Rui Wei, and Wenjuan Jiang, and Jiqing Su, and Lili He, and Zhen Yang, and Wuzhong Jiang
May 2013, Journal of radiation research,
Rui Wei, and Wenjuan Jiang, and Jiqing Su, and Lili He, and Zhen Yang, and Wuzhong Jiang
October 2015, Oncology letters,
Rui Wei, and Wenjuan Jiang, and Jiqing Su, and Lili He, and Zhen Yang, and Wuzhong Jiang
December 2013, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
Rui Wei, and Wenjuan Jiang, and Jiqing Su, and Lili He, and Zhen Yang, and Wuzhong Jiang
July 2017, International journal of radiation oncology, biology, physics,
Rui Wei, and Wenjuan Jiang, and Jiqing Su, and Lili He, and Zhen Yang, and Wuzhong Jiang
January 2018, American journal of therapeutics,
Copied contents to your clipboard!